Hope Ryan, APRN
Nurse Practitioner · Portsmouth, RINPI 1093702110
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Abbott at 37.6% of the total. Reporting peaked in 2021 at $362 and has fallen 74.6% since, to $92 in 2025.
Across 34 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$252
- Novo Nordisk$98
- AbbVie$82
- Dexcom, Inc.$56
- Mannkind Corporation$38
- Cequr Corporation$38
- plus $105 from 5 others
What the payments were for
- Food & beverage$62894%
- Education$122%
- Other$304%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $252 |
| Novo Nordisk | 5 | $98 |
| AbbVie | 4 | $82 |
| Dexcom, Inc. | 3 | $56 |
| Mannkind Corporation | 2 | $38 |
| Cequr Corporation | 2 | $38 |
| Boehringer Ingelheim | 1 | $27 |
| Nevro Corp. | 1 | $25 |
| Medtronic | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$669 in reported general payments places this provider in the 85th percentile of 396 nurse practitioner providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 331 | $307,429 |
| OzempicSemaglutide | 265 | $294,772 |
| TrulicityDulaglutide | 100 | $104,135 |
| MounjaroTirzepatide | 92 | $95,399 |
| FarxigaDapagliflozin Propanediol | 93 | $63,984 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $62,190 |
| Tresiba Flextouch U-200Insulin Degludec | 75 | $61,804 |
| RybelsusSemaglutide | 44 | $49,796 |
| TradjentaLinagliptin | 71 | $40,467 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $34,909 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $31,198 |
| JanuviaSitagliptin Phosphate | 27 | $27,392 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $27,380 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $22,383 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $14,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $27 | $347,896402 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $98 | $346,981325 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $12 | $208,764249 claims |
| AbbVieSynthroid | $82 | $5,79775 claims |
| Cequr CorporationCequr Simplicity | $38 | $5,52513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 396 nurse practitioner providers in Rhode Island.
Other nurse practitioner in Portsmouth
- Linda YoungLincoln$19K
- Lynne GlaserCumberland$17K
- Stephanie CostaWarwick$9K
- Maria SilvaJohnston$7K
- Natalie DriscollMiddletown$6K
- Lea KellyProvidence$5K
- Kathleen ParkerWarwick$5K
- Priscilla PonteEast Providence$5K
- Jennifer JohnsonNarragansett$5K
- Heather GlennWarwick$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.